När Entreprenad och Teknik inte levererar, räddar Transport kvartalet med rejäl ökning av omsättning...
Redeye provides a research update following the Q2 report recently published by Magle.
* EBIT was 35% better than ABGSC and 27% vs cons * Order backlog +18% y-o-y, plus major Uppsala tram...
Envar levererade ett rekordstarkt Q2’26 med en nettoomsättning på 53,7 MSEK, motsvarande en tillväxt...
Redeye provides its initial take on Acarix's Q2 report, which came in line with estimates and contai...
DOC shrugged off the weak Middle East situation in Q1.
Yesterday, INDUS released its H1 26 report. As outlined by preliminary figures published end of July...
Relais Q2 adjusted EBITA of EUR 8m was up 6% y/y and came 14% below Modular Finance consensus of EUR...
Redeye considers AAC's Q2 to be solid with net sales of SEK112m (+52% y/y) landing 1% above our SEK1...
Redeye provides its initial take on Moberg Pharma's Q2 report, which saw sales exceed expectations a...
Q2 adjusted EBITDA was EUR 3.1m, clearly above our estimate of EUR 2.
Net sales was EUR 73.1m (LSEG consensus EUR 73.5m) in Q2.
Redeye comments on Embracer’s Q1-results which were stronger-than-expected driven by solid growth in...
Taaleri's Q2 results were largely in line with our expectations on group key figures, although we no...
The main highlight of the second quarter was the clear improvement in order bookings including four ...
* Cost savings to offset sales decline in 2026e... * .
* Beat across all three segments * 34% sales and 65% EBIT beat * '26e/'27e group EBIT raised 16%/8% ...
Redeye leaves a comment following AlzeCure’s announcement that it has received the full USD12m upfro...
Redeye provides its initial take following the release of Argo's Q2 2026 report.
* Adj. EBIT 0.1m, vs ABGSC 0.1m and FactSet cons -0.